论文部分内容阅读
目的 探讨小剂量喹硫平治疗失眠症患者的临床疗效和安全性.方法 将56例失眠症患者按入组先后顺序分成研究组和对照组,每组28例,研究组口服喹硫平治疗,对照组口服右佐匹克隆治疗,观察4周.于治疗前后采用睡眠障碍评定量表评定临床疗效,副反应量表评定不良反应.结果 治疗1周末起两组睡眠障碍评定量表评分均较治疗前显著下降(P0.05).治疗4周末研究组总有效率为88.5%,对照组为85.2%,两组总有效率比较差异无显著性(X2=0.00,P>0.05).研究组不良反应发生率为30.8%,对照组为25.9%,两组不良反应发生率比较差异无显著性(X2=0.15,P>0.05).结论 小剂量喹硫平治疗失眠症患者疗效显著、安全性高,与右佐匹克隆相当,值得临床推广应用.“,”Objective To explore the efficacy and safety of low-dose quetiapine in the treatment of insomnia. Methods Fifty-six insomnia patients were assigned into study and control group of 28 ones each according to admission order,study group took orally quetiapine and the controls did eszopiclone for 4 weeks. The efficacies were assessed with the Sleep Dysfunction Rating Scale (SDRS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS). Results Since the end of the 1st week the SDRS scores of both groups lowered more significantly compared with pretreatment (P0.05). At the end of the 4th week total effective rate was respectively 88.5% in study and 85.2% in control group,which showed no significant difference (X2=0.00,P>0.05). The incidence of adverse reactions was respectively 30.8% in study and 25.9% in control group,which showed no significant difference (X2=0.15,P>0.05). Conclusion Low-dose quetiapine has better efficacy and higher safety equivalent to eszopiclone in the treatment of insomnia.